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BACKGROUND: Lactate dehydrogenase (LDH) represents a predictive factor in colorectal cancer patients treated with the angiogenesis
inhibitor PTK/ZK. We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line
bevacizumab.
METHODS: Metastatic colorectal cancer treated with first-line bevacizumab was eligible. A control group including all consecutive
patients treated with chemotherapy alone was also considered. Pre-treatment LDH serum levels were collected for all cases.
RESULTS: Median progression-free survival (PFS) in the control group for patients with high and low LDH levels was 4.2 and 8 months,
respectively (P¼ 0.0003). Median overall survival (OS) was 19.6 and 34.9 months for patients with high and low LDH levels,
respectively (P¼ 0.0014). In the bevacizumab group, partial responses were seen in 14 (58%) high-LDH and 8 (14%) low-LDH
patients (P¼ 0.0243), respectively, median PFS was 7.3 and 8.5 months, respectively (P¼ 0.2), and median OS was 22 and 26.6
months, respectively (P¼ 0.7).
CONCLUSION: High LDH levels correlated with worse prognosis. Bevacizumab seemed capable of improving clinical outcome in this
specific group of patients who usually present with an adverse natural history. The improved response rate also suggests a role for
LDH as a predictive marker.
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The VEGF-driven tumour pathway has been demonstrated to
represent a novel therapeutic target for an innovative class
of antineoplastic agents. Among these antiangiogenetic-targeted
treatment modalities, the anti-VEGF monoclonal antibody
bevacizumab has become a new standard of care for first-line
treatment of metastatic colorectal cancer (Douillard et al, 2000;
Hurwitz et al, 2004; Koehne et al, 2005).
The expanding role of anti-VEGF treatment for metastatic
colorectal tumour patients, along with the growing number of
cases potentially requiring such a treatment approach, made the
need for a reliable identification of responding tumours increas-
ingly crucial (Folkman, 1971).
However, if on the one hand clinical reports with the use of
bevacizumab have shown promising results, on the other hand in
these trials no predictive markers of response or resistance were
identified.
The biological link between hypoxia, lactate dehydrogenase
(LDH) levels and the tumour-driven angiogenesis pathway
through the abnormal activation of the hypoxia-inducible factor
1-a (HIF1-a) is well established. Hypoxia-inducible factor 1-a is an
important transcription factor that upregulates a series of genes
involved in glycolytic metabolism, angiogenesis, cell survival
and erythropoiesis. Among the others, HIF1-a also regulates
transcription of several glycolytic enzymes, such as LDH (Maxwell
et al, 2001). More specifically, it has been suggested that HIF1-a
overexpression was linked to the LDH-5 isoform activity
(Koukourakis et al, 2003).
In preclinical models, upregulation of LDH has been suggested
to ensure both an efficient anaerobic/glycolytic metabolism and a
reduced dependence on oxygen under hypoxic conditions in
tumour cells.
As LDH and pro-angiogenesis factors are regulated by the same
HIF1-a-driven molecular pathway, high LDH levels are concomi-
tantly present along with abnormal activation of the VEGF
pathway (Harris, 2002).
According to this biological assumption, Azuma et al (2007)
demonstrated that high LDH serum levels were associated with
tumour overexpression of VEGFA and VEGFR-1. As a clinical
consequence, it has been speculated that LDH levels may represent
an indirect indicator of activated tumour angiogenesis and
ultimately of worse prognosis (Tas et al, 2001a, b).
In colorectal cancer, LDH-5 overexpression has been demon-
strated to significantly correlate with an increased risk of
metastases, and high LDH serum levels have been implicated
in determining a worse prognosis (Koukourakis et al, 2005;
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Wu et al, 2010). This finding has been confirmed in other tumour
types as well (Brizel et al, 2001; Yuce et al, 2001).
The role of LDH in patients receiving antiangiogenic therapy is
more controversial. Available evidences in this setting are limited
to those deriving from the CONFIRM-1 and -2 trials. In these studies,
PTK/ZK (vatalanib), an oral inhibitor of VEGF receptors, was used
in combination with chemotherapy (FOLFOX) for, respectively,
first- and second-line therapy of advanced colorectal cancer (Hecht
et al, 2011; Van Cutsem et al, 2011). Both trials did not meet the
primary end point. However, in an exploratory post hoc analysis,
median progression-free survival (PFS) improved with the use of
PTK/ZK in patients with high LDH serum levels, thus suggesting
that LDH might be a predictive marker for antiangiogenic treatment.
Recently, Koukourakis et al (2011) also demonstrated that
serum LDH and tissue LDH-5 are complementary features that
may help characterising the activity of LDH in colorectal cancer.
On the other hand, data in colorectal cancer patients receiving
first-line bevacizumab are lacking and could be relevant for treatment
strategy and therapeutic decision in clinical practice. The aim of our
study was to explore a possible link between pre-treatment LDH
levels and clinical outcome in advanced colorectal cancer patients
treated with first-line chemotherapy and bevacizumab.
PATIENTS AND METHODS
Patient selection
All patients with histologically proven metastatic colorectal cancer
consecutively treated with a first-line chemotherapy doublet and
bevacizumab at our Institution were eligible for our analysis.
A historical control group was also created, including all
consecutive histologically proven metastatic colorectal cancer
patients treated at our Institution with a chemotherapy doublet
before the introduction of bevacizumab in clinical practice. Pre-
treatment LDH serum levels were collected for all patients.
The following first-line chemotherapy doublets were used:
modified FOLFIRI (irinotecan 180mgm2 d1, 5FU bolus 400mgm2
d1, 5FU 2400mgm2 continuous infusion for 46h every 2 weeks)
or FOLFOX-6 (oxaliplatin 85mgm2 d1, 5FU bolus 400mgm2 d1,
5FU 2400mgm2 continuous infusion for 46h, every 2 weeks) or
XELOX (oxaliplatin 130mgm2 d1, capecitabine 2000mgm2 d1 to
14 every 3 weeks) either in combination with bevacizumab (5mgkg1
every 2 weeks or 7.5mgkg1 every 3 weeks) or without bevacizumab.
Tumour response was evaluated every 8 weeks by clinicians’
assessment and according to the Response Evaluation Criteria in
Solid Tumors (RECIST).
Statistical analysis
Statistical analysis was performed with the MedCalc package
(MedCalc v.9.4.2.0, MedCalc Software bvba, Mariakerke, Belgium).
Receiver operating characteristics (ROC) curve analysis was
performed to determine a cutoff value for pre-treatment LDH levels.
The association between categorical variables was analysed by
w2-test. Survival distribution was estimated by the Kaplan–Meier
method. Significant differences in probability of relapsing between
the strata were evaluated by log-rank test. Cox multiple regression
analysis was used to assess the role of variables that resulted to be
significant at univariate analysis.
Tested variables included gender (male vs female), age (o65 vs
X65 years), grade of tumour differentiation (well vs moderately
differentiated and undifferentiated), Eastern Cooperative Oncology
Group Performance Status Scale (ECOG PS) (o2 vsX2) and LDH
serum level (p588 vs 4588mg dl1).
The heterogeneity of the effect of LDH levels between
bevacizumab and historical control group was explored by using
a statistical test for interaction, applied through a Cox model for
PFS and overall survival (OS).
A significant level of 0.05 was chosen to assess the statistical
significance.
For statistical analysis, OS and PFS were defined, respectively, as
the interval between the start of chemotherapy to death or last follow-
up visit, and as the interval between the start of chemotherapy to
clinical progression or death, or last follow-up visit if not progressed.
RESULTS
Globally, 220 patients with advanced colorectal cancer receiving
first-line chemotherapy were available for our analysis. In all, 82
patients were treated with a chemotherapy doublet (either
oxaliplatin or irinotecan in combination with fluoropyrimidines)
in combination with bevacizumab (bevacizumab group; accrual
interval 2005–2011), whereas the remaining 138 patients received
chemotherapy (either oxaliplatin or irinotecan in combination
with fluoropyrimidines) alone (historical control group; accrual
interval 1999–2005). The two groups of patients were comparable
for all major clinical characteristics such as age at diagnosis, sex,
metachronous vs synchronous metastatic involvement, previous
adjuvant chemotherapy, number of metastatic sites and proportion
receiving second-line treatment (Table 1). The cutoff point with
the highest sensitivity and specificity for estimating pre-treatment
LDH serum levels as a function of treatment of clinical activity was
set at p588mgdl-1 after ROC curve analysis (Figure 1). Conse-
Table 1 Patients characteristics
N
Median age
(range) Males (%)
Metachronous
disease (%)
Prior adjuvant
chemotherapy (%)
Metastatic
involvement
(A–B–C–D) 2nd line (%)
Bevacizumab group 82 61 (29–75) 52 (64%) 52 (64%) 40 (48%) 40 (48%) A 61 (75%)
10 (12%) B
18 (22%) C
14 (18%) D
Control group 138 63 (29–77) 91 (66%) 90 (65%) 62 (44%) 63 (45%) A 103 (75%)
18 (14%) B
30 (22%) C
27 (19%) D
All 220 61 (29–77) 153 (65%) 142 (64%) 102 (46%) 103 (47%) A 164 (75%)
28 (13%) B
48 (22%) C
41 (18%) D
Abbreviations: A¼ liver involvement only; B¼ lung involvement only; C¼ liver+lung involvement; D¼ other metastatic sites.
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quently, patients showing a pre-treatment LDH serum level
X588mgdl1 were classified as high-LDH patients, in contrast to
patients with pre-treatment LDH serum level lower than 588mg
dl1 (low-LDH patients). Globally, 44 patients (20%) showed high
pre-treatment LDH levels.
Role of pre-treatment LDH levels in the historical control
group
In all, 138 patients were available for analysis in this group. Of
these, 49 patients showed a partial response (35%), 1 patient
obtained a complete remission (1%), 32 patients achieved a stable
disease (23%) and 40 patients (29%) progressed during che-
motherapy. The remaining 16 patients (12%) were not assessable
for response. In the chemotherapy-alone group, 20 patients (15%)
had high pre-treatment LDH levels. The remaining 118 patients
(85%) presented with low pre-treatment LDH levels. The two
subgroups of patients were comparable for all major clinical
characteristics (Table 1).
In high- and low-LDH patients, we observed a partial response
in 4 (20%) and 46 (39%) patients, respectively (P¼ 0.1671),
whereas progressive disease was observed in 14 (70%) and 26
(22%) patients with, respectively, high and low pre-treatment
LDHlevels (Po0.0001; Table 2).
Median PFS and OS for patients in the historical control group
were, respectively, 7.2 and 29.7 months. In this group, pre-treatment
LDH levels were statistically related to both worse median PFS
and OS. In particular, patients with high LDH levels achieved a
median PFS of 4.2 months, whereas median PFS was 8 months for
patients with low pre-treatment LDH levels (P¼ 0.0003; HR: 0.2973;
95% CI: 0.0318–0.3543; Figure 2 and Table 2). Median OS was 19.6
and 34.9 months for patients with high and low pre-treatment LDH
levels, respectively (P¼ 0.0014; HR: 0.2484; 95% CI: 0.0188–0.3884;
Figure 3 and Table 2). Among the other tested clinical parameters,
median OS improved in male patients (median OS in male vs female
patients: 33.5 vs 17.8 months, respectively, P¼ 0.007) and in patients
with a well-differentiated tumour (median OS in patients with well-
differentiated vs moderately differentiated and undifferentiated
tumours: not reached vs 25.5 months, respectively, P¼ 0.007). At
multivariate analysis, only LDH serum level maintained an
independent prognostic value.
Role of pre-treatment LDH levels in the bevacizumab
group
In all, 82 patients were available for analysis in this group. Of these,
22 patients showed a partial response (27%), 40 patients obtained a
stable disease (49%), whereas 12 patients (15%) progressed during
treatment. In the remaining eight patients (9%), response was not
assessable. No complete remissions were observed. In the
bevacizumab group, 24 patients (29%) had high pre-treatment
LDH levels. The remaining 58 patients (71%) presented with low
pre-treatment LDH levels. The two subgroups of patients were
comparable for all major clinical characteristics (Table 1). In high-
and low-LDH patients, we observed a partial response in 14 (58%)
and 8 (14%) patients, respectively (P¼ 0.0243), whereas progres-
sive disease was observed in 2 (8%) and 10 (17%) patients with,
respectively, high and low pre-treatment LDH levels, respectively
(P¼ 0.48; Table 2). Median PFS was 8.5 and 7.3 months,
respectively, for high- and low-LDH patients (P¼ 0.2;
HR: 0.6360; 95% CI: 0.2528–1.4185) (Figure 2 and Table 2).
Median OS survival was 26.6 and 22 months, respectively, for
patients showing high or low pre-treatment LDH levels (P¼ 0.7;
HR: 0.8480; 95% CI: 0.2307–2.9563) (Figure 3 and Table 2).
All the other tested variables (age, gender, ECOG PS and tumour
grade) failed to show a significant correlation with survival
parameters.
Combined results
We compared results from the bevacizumab and control groups
according to pre-treatment LDH levels. No statistically significant
differences were noticed for median OS. In the high-LDH group,
response rate was higher in patients treated with bevacizumab
(58% vs 20%, P¼ 0.01). Accordingly, median PFS in the high-LDH
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Figure 1 Receiver operating characteristics analysis based on pre-
treatment LDH serum levels results with OS as end point. In this model,
sensitivity was 63.64% (95% CI: 40.7–82.8) and specificity was 84.62%
(95% CI: 71.9–93.1). Area under the curve was 0.689, P¼ 0.0077.
Table 2 Response rate according to pre-treatment LDH levels in the bevacizumab group and in the control group
Control group Bevacizumab group
LDH o588 LDH 4588 P-value LDH o558 LDH 4588 P-value
Partial+complete response 46 (39%) 4 (20%) 0.1671 8 (14%) 14 (58%) 0.0243
Stable disease 46 (39%) 2 (10%) 0.0237 40 (69%) 8 (36%) 0.0063
Progressive disease 26 (22%) 14 (70%) o0.0001 10 (17%) 2 (8%) 0.48
118 20 58 24
138 82
Abbreviation: LDH¼ lactate dehydrogenase.
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group was in favour of patients treated with bevacizumab
(P¼ 0.006; HR: 3.6257; 95% CI: 1.5776–16.0715; Figure 4). The
interaction test between LDH levels and treatment effect, in the
bevacizumab group and historical control group, suggested that
the relation of LDH levels with improved outcome was signifi-
cantly associated with the effect of bevacizumab in terms of PFS
(P¼ 0.02), but not in terms of OS (P¼ 0.07).
DISCUSSION
The role of LDH as a marker of clinical outcome in advanced
colorectal cancer patients has been suggested in different clinical
series. Previous reports in colorectal cancer patients indicated, in
fact, that LDH upregulation was associated with an increased risk
of both nodal and distant metastases (Tas et al, 2001a), and that
high LDH serum levels could predict a decreased median OS and
have a prognostic impact (De Gramont et al, 2000; Tas et al, 2001b;
Tournigand et al, 2004, 2011). This analysis suggested that pre-
treatment LDH levels could be considered a relevant factor for risk
evaluation in colorectal cancer patients receiving chemotherapy.
Besides representing a possible indicator of prognosis, LDH may
also have a role in patient stratification for clinical trials
investigating first-line therapy in colorectal tumours. However,
although a biological relationship between LDH levels, tumour
hypoxia and angiogenesis has been indicated in pre-clinical and
clinical studies, the role of pre-treatment LDH levels in patients
receiving anti-VEGF therapy remains substantially unexplored.
The only available data about the role of LDH levels and an
antiangiogenic treatment are those deriving from the recently
published trials investigating PTK/ZK (vatalanib), an oral inhibitor
of VEGF receptors, in first- and second-line therapy of advanced
colorectal cancer. Both trials did not reach their primary end point,
but in an exploratory post hoc analysis median PFS improved with
the use of PTK/ZK in patients with high serum LDH level. No
meaningful effect was seen on either response rate or OS. The
strong association between LDH-5 expression and the activated
VEGF pathway demonstrated in a study by Koukourakis et al
(2006) may represent a biological rationale to explain anti-VEGF
activity in the presence of high LDH levels.
Interestingly, our analysis suggested that metastatic colorectal
cancer patients treated with bevacizumab and showing high
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Figure 2 (A) Kaplan–Meier curves for median PFS of colorectal cancer
patients in the historical control group showing high pre-treatment LDH
serum levels (- - - - - - -) and low pre-treatment serum levels (———)
(4.2 vs 8 months, P¼ 0.0003). (B) Kaplan–Meier curves for median PFS
of colorectal cancer patients in the bevacizumab group showing high
pre-treatment LDH serum levels (- - - - - - -) and low pre-treatment serum
levels (———) (8.5 vs 7.3 months, P¼ 0.2).
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Figure 3 (A) Kaplan–Meier curves for median OS of colorectal cancer
patients in the historical control group showing high pre-treatment LDH
serum levels (- - - - - - -) and low pre-treatment serum levels (———)
(19.6 vs 34.9 months, P¼ 0.0014). (B) Kaplan–Meier curves for median
OS of colorectal cancer patients in the bevacizumab group showing high
pre-treatment LDH serum levels (- - - - - - -) and low pre-treatment serum
levels (———) (26.6 vs 22 months, P¼ 0.7).
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pre-treatment LDH levels experienced an improved probability of
response and an equivalent median PFS and OS when compared
with patients presenting with low LDH levels. These findings may
be considered in accordance with the observations derived
from the CONFIRM-1 and -2, thus confirming an improved
clinical outcome for patients with high LDH levels when treated
with an anti-VEGF therapy. However, in contrast to the
PTK/ZK results, we evidenced an improved response rate in the
high-LDH group treated with bevacizumab (which is not present in
neither the Hecht nor the Van Cutsem study; Hecht et al, 2011;
Van Cutsem et al, 2011), whereas no advantages could be seen in
our series with regard to median PFS. Many factors may have
contributed to these apparently different profiles of activity. The
different antiangiogenic treatment used (an anti-VEGF monoclonal
antibody in our case vs an oral VEGF receptor tyrosine kinase
inhibitor in the CONFIRM trials) should be considered relevant.
Although we have limited data on the activity profile of PTK/ZK,
we can in fact assume that vatalanib may be more effective in
improving PFS than response rate in the high-LDH subgroup of
patients, whereas bevacizumab demonstrated also an impact in
determining response rate across trials. We also know that radio-
logical evaluation of response could represent a confounding factor
for patients receiving antiangiogenic treatment (Chun et al, 2009).
In our experience, treatment with bevacizumab seemed to be
capable of improving clinical outcome in a specific group of
patients who usually present with an adverse natural history. In
this group of patients, bevacizumab seemed to act as a clinical
outcome ‘equaliser’ inducing a reversal of a poor prognosis. The
finding of an improved response rate and median PFS for patients
with high pre-treatment LDH levels receiving bevacizumab over
patients with the same LDH levels not receiving bevacizumab
could represent a corroboration to this observation.
The interaction test between LDH levels and treatment effect, in
the bevacizumab group and historical control group, in fact
suggested that the improved outcome in high-LDH patients was
significantly associated with the effect of bevacizumab on PFS. Our
results, if confirmed in a larger data set, may have relevant
implications for the choice of a first-line treatment for advanced
colorectal cancer patients. We can in fact speculate that, in
colorectal cancer patients with high LDH levels, the use of an
antiangiogenic treatment in combination with chemotherapy may
improve clinical outcome and allow a better management of the
metastatic disease.
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